Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Germany’s Fresenius raises 2024 forecast after Q3 beat, shares rise
    Finance

    Germany’s Fresenius raises 2024 forecast after Q3 beat, shares rise

    Published by Uma Rajagopal

    Posted on November 6, 2024

    2 min read

    Last updated: January 29, 2026

    The image features the Fresenius logo alongside a financial data graphic, highlighting the company's Q3 earnings beat and raised 2024 forecasts. This visual represents Fresenius' strong performance in the finance sector.
    Fresenius logo with financial data graphic illustrating Q3 earnings beat - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:financial managementinvestmentcorporate strategyFinancial performance

    By Tristan Veyet and Rafal Wojciech Nowak

    (Reuters) – Germany’s Fresenius raised its full-year outlook on Wednesday after beating third-quarter expectations, citing strong performances at its Kabi and Helios divisions and deleveraging efforts paying off, sending shares up.

    The healthcare group said it expects organic revenue growth of 6%-8%, from a previously anticipated 4%-7%.

    It also raised its forecast of constant currency earnings before interests and taxes (EBIT) before special items growth to 8%-11% from 6-10%.

    Fresenius’s shares shot up, rising 6.2% at 0757 GMT.

    Fresenius reported third-quarter revenue of 5.30 billion euros ($5.69 billion) and EBIT before special items of 522 million euros, beating a company-provided consensus by 1.7% and 3.4% respectively.

    “The group’s deleveraging efforts are ahead of our expectations,” Berenberg writes in a note, adding the company also benefited from higher contributions from associated income, notably Fresenius Medical Care’s.

    Dialysis specialist Fresenius Medical Care slightly raised the lower end of its 2024 operating profit forecast range on Tuesday after posting quarterly earnings above expectations, helped by cost savings and as its U.S. business recovers.

    Fresenius’ net debt decreased by around 11% compared to 2023’s end, with a net debt to EBITDA ratio of 3.24.

    Both Kabi and Helios continue to deliver consistent and sustained financial performance,” CEO Michael Sen said in a statement.

    Since taking the helm in October 2022, Sen has been revamping the organization to reduce expenditures and liabilities following a drop in profits at its previous dialysis unit, Fresenius Medical Care.

    This restructuring initiative has prioritized Fresenius Kabi, a producer of generic hospital medications, and Helios, which operates a network of hospitals in Germany and Spain.

    The German firm added it already accomplished in the first nine months of the year its cost savings objective of around 400 million euros on an EBIT level, originally planned for 2025.

    ($1 = 0.9315 euros)

    (Reporting by Tristan Veyet and Rafal W. Nowak in Gdansk; Editing by Varun H K and Bernadette Baum)

    Frequently Asked Questions about Germany’s Fresenius raises 2024 forecast after Q3 beat, shares rise

    1What is EBIT?

    EBIT stands for Earnings Before Interest and Taxes. It is a measure of a firm's profit that includes all incomes and expenses except interest and income tax expenses.

    2What is organic revenue growth?

    Organic revenue growth refers to the increase in revenue generated from a company's existing operations, excluding any revenue from acquisitions or mergers.

    3What is deleveraging?

    Deleveraging is the process of reducing debt by paying off existing loans, which can improve a company's financial stability and reduce its debt-to-equity ratio.

    Previous Finance PostUK homebuilder Persimmon flags cost concerns after strong Q3 sales
    Next Finance PostItaly’s INWIT sees FY revenue at lower end of guidance, on stiff competition
    More from Finance

    Explore more articles in the Finance category

    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    Image for Dog food maker Ollie acquired by Spain’s Agrolimen
    Dog food maker Ollie acquired by Spain’s Agrolimen
    Image for Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    View All Finance Posts